HSV-2 gG Activators
HSV-2 gG Activators largely consists of antiviral agents that indirectly influence the activity or expression of HSV-2 glycoprotein G (gG). This protein plays a role in the virus's entry into host cells and in evading the immune system. The primary strategy for influencing HSV-2 gG indirectly involves targeting the viral replication cycle or enhancing the host's immune response against the virus.
Agents like Interferon-alpha and Imiquimod work by stimulating the immune system to more effectively combat viral infections. This heightened immune response can suppress viral replication and, consequently, the expression of viral proteins. Additionally, compounds like Docosanol interfere with the viral entry process by inhibiting the fusion of the viral envelope with the host cell membrane. This action can influence the function of viral glycoproteins, including gG, which are critical for the entry process.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod enhances immune responses and could indirectly affect HSV-2 protein expression including gG. | ||||||
Trifluorothymidine | 70-00-8 | sc-222370 sc-222370A | 100 mg 1 g | $179.00 $500.00 | 1 | |
Trifluridine is used to treat HSV keratitis and might have an indirect effect on HSV-2 protein expression. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $63.00 $110.00 $214.00 | 1 | |
Ribavirin, an antiviral drug, could indirectly impact HSV-2 protein expression through its antiviral activities. | ||||||
Penciclovir | 39809-25-1 | sc-203183 | 100 mg | $260.00 | ||
Penciclovir, an antiviral agent against HSV, may indirectly influence HSV-2 gG expression by inhibiting viral replication. | ||||||